Knockdown of HMGA2 impairs the in vivo reconstitution potential of CB-derived CD34⁺cells. (A) Overview of the in vivo transplantation assay for HMGA2-deficient cells. (B) Human CD45⁺GFP⁺ chimerism in mice transplanted with shHMGA2-1–transduced cells as analyzed in peripheral blood after 7 and 14 weeks. (C) Representative FACS plots showing BM engraftment of primary recipient NSG mice 14 weeks after transplantation. (D) Accumulated data for huCD45⁺GFP⁺ cell engraftment, myeloid (CD15/CD33⁺), and lymphoid (CD19⁺) lineage distribution, as well as levels of HSC engraftment (CD34⁺CD38⁻ cells) measured in huCD45⁺GFP⁺ graft in BM of primary recipient NSG. (E) Human CD45⁺GFP⁺ engraftment in secondary recipients analyzed 20 weeks posttransplantation. *P < .05; **P < .01.